Hims & Hers Health (HIMS) Convertible Debt (2025 - 2026)

Hims & Hers Health (HIMS) posted Convertible Debt of $974.1 million for Q1 2026, little changed sequentially from $972.6 million in Q4 2025.

Hims & Hers Health (HIMS) Convertible Debt (2025 - 2026) Analysis & Trends

Hims & Hers Health has reported Convertible Debt for 2 years, with the latest figure at $974.1 million in Q1 2026.

Quarterly Convertible Debt changed N/A year-over-year to $974.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $974.1 million (changed N/A YoY) and the FY2025 annual result came in at $972.6 million, changed N/A from the prior year.
Convertible Debt held at $974.1 million in Q1 2026 per HIMS's latest filing, from $972.6 million in the prior quarter.
Over five years, Convertible Debt peaked at $974.1 million in Q1 2026 and troughed at $969.5 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-
10	Hims & Hers Health	7.42 Bn	6.57 Bn	480.80 Mn

Download Data